Urology News and Research

Latest Urology News and Research

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

EAU honours urological experts at 25th Anniversary Congress

On 16 April 2010 the European Association of Urology opened its 25th Anniversary Congress. During the ceremony, several urological experts were honoured with awards for the outstanding work they did for the urological community. EAU Secretary General Per-Anders Abrahamsson handed them out.

17 Apr 2010

EAU launches new website

The EAU recently launched its new website. Online efforts are continued under the same name: www.uroweb.org. But everything else has been redesigned in line with the latest internet trends - user-friendliness, interactivity, elegance. Prof. Manfred Wirth, EAU Executive Member Communication, says: "The EAU is a dynamic organisation.

17 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets.

16 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

The Lockheed Martin Corp. announced today a pledge of $4 million to benefit the UCLA Health System's Operation Mend program, which provides reconstructive surgeries and other health care needs to U.S. military personnel wounded in Iraq and Afghanistan.

13 Apr 2010

EDAP's Sonolith i-move lithotripter receives European approval

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the European approval of its new lithotripter, the Sonolith i-move. The EDAP sales team and distributors will begin marketing Sonolith i-move immediately and will officially introduce the product to distributors, partners and visiting urologists at the European Association Urology (EAU) congress, Booth #14, from April 17-19, 2010 in Barcelona, Spain.

12 Apr 2010

Over 12,000 participants already registered for 25th Anniversary EAU Congress

The upcoming 25th Anniversary EAU Congress in Barcelona from April 16 to 20 promises to be one of the EAU's biggest meetings in recent years with around 12,100 participants already registered to attend the annual urological event.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

OSU-CG12 agent kills cancer cells through energy restriction: Study

Cancer cells grow so fast that they can outstrip their blood supply, leaving them short of oxygen. The cells then produce energy in a way that needs less oxygen but more sugar.

8 Apr 2010

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the United States Bankruptcy Code.

8 Apr 2010

Unique collaboration in fetal medicine among Columbus' healthcare professionals

The Columbus Fetal Medicine Collaborative has been formed by Mount Carmel Health System, OhioHealth, The Ohio State University Medical Center and Nationwide Children's Hospital joining together to provide optimal outcomes for high-risk expectant mothers and their babies with suspected fetal abnormalities.

8 Apr 2010

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Kidney damage associated with chronic reflux is the fourth leading cause of chronic kidney disease and is the most common cause of severe hypertension in children. Doctors and researchers at Nationwide Children's Hospital have developed a new mouse model of vesicoureteral reflux, a common childhood condition that can lead to chronic kidney disease in children.

7 Apr 2010

Future of health care in practice at Cincinnati Children's Hospital Medical Center

The future of health care is here. And it's in practice at Cincinnati Children's.

7 Apr 2010

Financial stake in surgery centers motivates doctors to operate more often

When doctors become invested in an outpatient surgery center, they perform on average twice as many surgeries as doctors with no such financial stake, according to a new study from the University of Michigan Health System.

7 Apr 2010

Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring biotech company Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

6 Apr 2010

New study to compare Botox against oral medications for urge incontinence in women

A new study is underway at Loyola University Health System to compare botulinum toxin A or Botox® versus common oral medications for urge incontinence in women. Urge incontinence is urinary incontinence with a strong or sudden need to urinate. Millions of women suffer in silence each day from this condition.

6 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

Health IT funding raises security concerns; Some hospitals face barrier to funding

"Two big questions yet to be answered with electronic health records are: Do they save money? And can they be made 100 percent secure? The verdict is still out on both. The thought of one's personal medical information being just a computer click away does not sit well with many consumers." The paper reviews several surveys from last year to note that "security is on everyone's mind" (Smith, 4/5).

6 Apr 2010